Biotech RadarJobs updated

COMPANY

Inventprise

HQ: Woodinville, WA source · inventprise.com ↗ · West Coast

Clinical Phase 2

Keywords: vaccine infectious disease mRNA Pneumococcal Vaccines Shigella Diarrhea Invasive Pneumococcal Disease PCV 20 IVT Shigella-04 IVT PCV-25

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults source ↗
  2. Trial start 2: Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants source ↗
  3. Trial start I: Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age. source ↗
  4. Trial start Phase 2: Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine source ↗
  5. Trial start Phase 1: Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine source ↗

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT06077656Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate VaccinePhase 2CompletedOct 25, 2023May 24, 2024 (actual)
NCT07205926First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young AdultsPhase 1RecruitingOct 9, 2025Jan 26, 2026 (estimated)
NCT06611371Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.IActive, not recruitingNov 12, 2024Aug 26, 2025 (actual)
NCT06790290Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants2Active, not recruitingJan 27, 2025Apr 3, 2025 (actual)
NCT05540028Study to Evaluate a 25-Valent Pneumococcal Conjugate VaccinePhase 1CompletedSep 28, 2022Jul 31, 2023 (actual)
Feedback